Akero Therapeutics, Inc. (AKRO) Earnings History
Net Loss8 years of earnings data (2017–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Akero Therapeutics, Inc. (AKRO) Earnings Overview
As of November 8, 2026, Akero Therapeutics, Inc. (AKRO) reported trailing twelve-month net income of -$252M. The company earned $-3.75 per diluted share over the past four quarters.
Looking at the long-term picture, AKRO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2017.
Akero Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$155M net income, -30.1% margin), HALO ($485M net income, 22.7% margin), ELVN (-$113M net income), AKRO has comparable earnings metrics. Compare AKRO vs MDGL →
AKRO Earnings vs Peers
Earnings metrics vs comparable public companies
AKRO Historical Earnings Data (2017–2024)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$252M | -66.1% | -$285M | $-3.75 | - | - |
| 2023 | -$152M | -35.5% | -$173M | $-2.89 | - | - |
| 2022 | -$112M | -11.2% | -$115M | $-2.87 | - | - |
| 2021 | -$101M | -27.3% | -$101M | $-2.89 | - | - |
| 2020 | -$79M | -81.0% | -$80M | $-2.52 | - | - |
| 2019 | -$44M | +46.5% | -$46M | $-2.90 | - | - |
| 2018 | -$82M | -1690.4% | -$14M | $-3.85 | - | - |
| 2017 | -$5M | - | -$5M | $-0.16 | - | - |
Download Data
Export AKRO earnings history in CSV or JSON format
Free sign-in required to download data
AKRO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AKRO — Frequently Asked Questions
Quick answers to the most common questions about buying AKRO stock.
What is AKRO earnings per share (EPS)?
AKRO trailing twelve-month (TTM) diluted EPS is $-3.75, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2024 is available in the table on this page.
What is Akero Therapeutics, Inc.'s net income?
Akero Therapeutics, Inc. (AKRO) trailing twelve-month net income is $-252M as of 2024. Earnings declined N/A year-over-year.
Is AKRO profitable?
AKRO is not currently profitable on a TTM basis, reporting a net loss of $-252M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AKRO's earnings growth rate?
AKRO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2024.
What are AKRO's profit margins?
Akero Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is AKRO growing earnings?
AKRO TTM EPS: $-3.75. Net income: $-252M. YoY earnings change: N/A.
What was AKRO's best earnings year?
Akero Therapeutics, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2024 and includes all annual and quarterly figures.
What were AKRO's earnings last quarter?
AKRO's most recent reported quarter was Q3 2025. Net income was $-82M with diluted EPS of $-0.99. For a full breakdown of all quarters, see the quarterly earnings table on this page.